Who is sponsoring NCT03340090?

NCT03340090 is sponsored by Medical University of Lodz.

What drugs are being tested in NCT03340090?

Interventions in NCT03340090: Medical Device Hemopatch-PEG-coated collagen patch.

What condition does NCT03340090 study?

NCT03340090 studies CHD - Coronary Heart Disease.

Is NCT03340090 still recruiting?

NCT03340090 is currently status unknown. Last updated 9 August 2019.

Last reviewed 2019-08-09 · How we verify

NCT03340090: Hemopatch

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of the Usefulness of Hemopatch in Coronary Artery Bypass Graft Surgery

Status unknown NA Last updated 9 August 2019

What this trial tests

NA trial testing Medical Device Hemopatch-PEG-coated collagen patch in CHD - Coronary Heart Disease in 200 participants. Status unknown.

Timeline

20 March 2018

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Medical University of Lodz
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	20 March 2018
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Poland

Drugs / interventions tested

Medical Device Hemopatch-PEG-coated collagen patch

Conditions studied

CHD - Coronary Heart Disease — all drugs for CHD - Coronary Heart Disease →

Sponsor

Medical University of Lodz

Who can join

18 and older, any sex, with CHD - Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aim is to assess polyethylene glycol (PEG) coated collagen patch (Hemopatch) on the quality of drainage after surgery, the length of hospital stay, the number of reoperations due to haemorrhage and treatment cost. The study will be conducted in 200 patients undergoing Coronary Artery Bypass Grafting (CABG) with the use of extracorporeal circulation and Internal mammary Artery (IMA) harvesting. Traditional method of haemostasis will be applied in 100 patients and Hemopatch will be additionally used in 100 subjects to prevent haemorrhage after IMA harvesting and sternum closure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Medical University of Lodz trials

Trials by the same sponsor.

NCT07391969 — Evaluation of SaCo VLMA for General Anesthesia for Laparoscopic Procedures · NA · not yet recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting
NCT06850597 — Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's D · Phase 2 · recruiting
NCT06917300 — Virtual Reality as a Digital Premed to Alleviate Pain and Anxiety Preoperatively in Patients Undergoing Spine Surgery · NA · recruiting
NCT06391216 — The Effect of Probiotic Supplementation on Mental Health in Healthy Volunteers · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03340090 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Lodz
Last refreshed: 9 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03340090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing